Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.

Research output: Contribution to journalArticle

Abstract

To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Behçet disease (BD).

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Rheumatology and Autoimmunity
Original languageEnglish
Pages (from-to)1906-1913
JournalJournal of Rheumatology
Volume42
Issue number10
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes